RxDoctor Payments DataLook up a doctor →

Celine Rivera, MD

Internal Medicine · Ogden, UTNPI 1407052772

Payments from drug & device makers

$11,494in general payments, 2019–2025

Across 672 payments — averaging $17.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Biohaven Pharmaceuticals, Inc.$750
  • Astellas Pharma US Inc$732
  • Daiichi Sankyo Inc.$714
  • AstraZeneca$703
  • Pfizer$654
  • plus $7K from 53 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)88$1,254
Biohaven Pharmaceuticals, Inc.1$750
Astellas Pharma US Inc43$732
Daiichi Sankyo Inc.23$714
AstraZeneca40$703
Pfizer46$654
Lilly USA, LLC45$620
Novo Nordisk43$590
AbbVie29$518
Novartis30$504
Boehringer Ingelheim26$502
Amarin Pharma, Inc.43$468
GSK28$419
Johnson & Johnson20$352
Merck23$344
Sanofi-aventis U.S. LLC21$291
Otsuka America Pharmaceutical, Inc.9$161
Bayer10$159
Sumitomo Pharma America, Inc.9$143
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC8$136
Regeneron Healthcare Solutions, Inc.1$106
Arbor Pharmaceuticals, Inc.7$101
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)5$97
Eisai Inc.5$82
Lundbeck LLC4$81
Dexcom, Inc.5$72
Axsome Therapeutics, Inc.4$69
Biohaven Pharmaceutical Holding Company Ltd.4$65
Phathom Pharmaceuticals, Inc.5$62
Nestle Healthcare Nutrition Inc.3$51
Idorsia Pharmaceuticals US Inc3$43
Sanofi Pasteur Inc.3$43
Amneal Pharmaceuticals LLC3$43
Lucid Diagnostics Inc.3$41
Corcept Therapeutics1$37
Ultragenyx Pharmaceutical Inc.2$34
Takeda Pharmaceuticals U.S.A., Inc.2$33
Otsuka Pharmaceutical Development & Commercialization, Inc.2$33
Seqirus USA Inc2$29
Exact Sciences2$28
Gilead2$27
Kowa Pharmaceuticals America, Inc.2$27
Edwards Lifesciences1$23
Boston Scientific1$21
Shire North American Group Inc1$19
Tandem Diabetes Care, Inc.1$19
Linus Health, Inc.1$18
Biogen1$18
Actelion Pharmaceuticals US, Inc.1$18
Sunovion Pharmaceuticals Inc.1$17
Melinta Therapeutics, LLC1$17
Xeris Pharmaceuticals, Inc.1$16
Mylan Specialty L.p.1$16
Currax Pharmaceuticals LLC1$14
Tactile Systems Technology Inc1$14
Ascensia Diabetes Care US Inc.1$13
E.r. Squibb & Sons, L.L.C.1$13
Medtronic1$12
Organon1$11

How this compares

$11,494 in reported general payments places this provider in the 90th percentile of 496 internal medicine providers in Utah.

See all internal medicine providers in Utah →

Medicare billing

Part B allowed, 2024
$96,302
Medicare patients
162
Services billed
1,118

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Ogden

See the full list for Utah →

Where these figures come from

Is this you, or does something look wrong? →